Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.

Phase 4

Completed

Brief Summary: Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (THR), total knee replacement (TKR), hip fracture (HF). The bleeding risk associated with this prescription is highly related to renal function evaluated by creatinin clearance (CrCl). In order to reduce the bleeding risk, it has been proposed to prescribe fondaparinux 1.5 mg/day in patients with a CrCl between 20 and 50ml/mn instead of 2.5mg/day (European MMA). In the meantime, this approval is essentially based on simulated pharmakinetic data without any support of clinical data.

prospective, multicentre, open-label study evaluating the safety profile of fondaparinux 1.5 mg/day, subcutaneously administered, in patients with a renal impairment defined by a CrCl between 20 and 30 ml/min and undergoing a major orthopaedic surgery.

Detailed Description: Fondaparinux 1.5mg/day subcutaneously administered during post-surgery 1 to 10 days with the 1st treatment administration performed 6 to 8 hours after the end of surgery.

Screening visit : \> 7 days before inclusion visit if THR and TKR Inclusion visit : day of surgery Visits with blood drawing: 3 visits scheduled during 1 to 10 days of treatment period Study end of treatment visit: D1 to D10 Study end visit: 1 month ± 15 days

Recruitment & Eligibility

Inclusion Criteria

• age > 18 years old,
- undergoing a major orthopaedic surgery (THR, TKR, HF) whatever procedure techniques are used, 1st indication or 2nd indication,
- requiring an antithrombotic prophylaxis,
- presenting a renal impairment defined by a creatinin clearance (CrCl) between 20 and 50 ml/min calculated by Cockcroft and Gault's formula,
- having signed the inform consent form.

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
1	fondaparinux 1.5 mg/day	patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery

Primary Outcome Measures

Name	Time	Method
Number of Patients With Major Bleedings Between Day 1 and Day 10.	10 day	evaluate between Day 1 and Day 10, the number of patients under study treatment who has affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of \>2 units of packed red blood cells or was associated with a fall in hemoglobin \>20 g/L.

Secondary Outcome Measures

Name	Time	Method
Number of Patients With Major Bleedings at 1 Month ± 5 Days.	45 day	evaluate the number of patients affected by major bleedings defined as fatal, involved a critical organ, treatment cessation, occurred at the surgical site and necessitated any medical intervention, or if it was overt and necessitated transfusion of \>2 units of packed red blood cells or was associated with a fall in hemoglobin \>20 g/L at 1 month ± 5 days.
Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism Between Day 1 and Day 10	10 days	Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) between Day 1 and Day 10.
Number of Patients With Symptomatic Deep Vein Thrombosis and Pumonary Embolism at 1 Month ± 5 Days	at 1 month ± 5	Evaluate the number of patients affected by symptomatic Deep Vein Thrombosis (any symptomatic distal and/or proximal deep-vein thrombosis) and Pumonary Embolism (symptomatic pulmonary embolism confirmed by objective tests) at 1 month ± 5 days.
Death at 1 Month ± 5 Days	1 month ± 5 days	Evaluate the total number of death at 1 month ± 5 days

Locations (29): GAERTNER Elisabeth
🇫🇷
Nice, France
RIPART Jacques
🇫🇷
Nimes, France
GARANGER Thierry
🇫🇷
Agen, France
BELLOUCIF Sadek
🇫🇷
Bobigny, France
BONNEMAISON Julie
🇫🇷
Bayonne, France
BEGOU Gérard
🇫🇷
Lyon, France
LETOURNEAU Bernard
🇫🇷
Dijon, France
LEMANISSIER Denis
🇫🇷
Le Mans, France
AUSSET Sylvain
🇫🇷
Clamart, France
CAPDEVILLA Xavier
🇫🇷
Montpellier, France
PERON Alain
🇫🇷
Nantes, France
CHAMBON Françoise
🇫🇷
Lyon, France
SZTARCK François
🇫🇷
Bordeaux, France
CHARRET Françoise
🇫🇷
Annonay, France
PEGOIX Michel
🇫🇷
Caen, France
LANGERON Olivier
🇫🇷
Paris, France
SCHOEFFLER Pierre
🇫🇷
Clermont-ferrand, France
TISSIER Dominique
🇫🇷
La Roche Sur Yon, France
CHEVALEREAUD Erick
🇫🇷
Niort, France
MAZUIRE Elisabeth
🇫🇷
Paris, France
RABUEL Christophe
🇫🇷
Paris, France
THERY Philippe
🇫🇷
Poitiers, France
FUZIER Régis
🇫🇷
Toulouse, France
BARRE Jeanne
🇫🇷
Reims, France
LIGNOT Sophie
🇫🇷
Rouen, France
DUVERGER Daniel
🇫🇷
Saint-saulve, France
MARTIN
🇫🇷
SAINt-ETIENNE, France
BAYLOT Denis
🇫🇷
Saint-etienne, France
COUVRET Claude
🇫🇷
Tours, France